Decades of laboratory studies have suggested that giving estrogen to either men or women after traumatic injury can decrease brain injury by 65 percent and increase survival by 65 percent. But no clinical trials have been done using estrogen in acute resuscitation situations – until now. Two local studies involving Baylor Research Institute in Dallas, Parkland Memorial Hospital and UT Southwestern Medical Center are underway to blind-test estrogen therapy in real-life settings. The studies each enrolled 50 participants between July 2009 and January 2012. Twenty-five received the estrogen therapy and 25 got a placebo. In the shock study, which involves low blood pressure and bleeding, subjects included those who had been in car crashes, shootings, and stabbings. In the other, people had fallen from buildings, had head injuries from car accidents, etc. Data analysis of pilot studies are expected to conclude later this year.
LDL cholesterol is a 27 carbon atom molecule as is Delalutin.
Progesterone is a molecule containing 21 or fewer carbon atoms.
Progesterone and pregnenolone are 21 carbon atom molecules.
DHEA – known as the mother of all hormones- is a 19 carbon atom molecule, as are androstenedione and testosterone. These three compounds are called androgens.
Anastrozole, an aromatase inhibitor, used here stops conversion of androgens (19 carbon atom steroids) to estrogens, which are 18 carbon steroids (estradiol, estriol, and estrone).
Prescription transdermal estrogen or testosterone can be used daily. They fine tune sexual performance.
From The Wall Street Journal of April 18, 2011: Women who start estrogen in their fifties reduce risk of coronary disease by 41% and heart attack risk by 46%. For women who wait until their seventies to start estrogen, there is an increase in colorectal cancer risk of 83%, and overall disease increase of 15%. Therefore, ladies, timing of the beginning of HRT is crucial, the earlier the better.
I attended the 33rd annual Breast Cancer Symposium at San Antonio, Texas December 8-12, 2010. It was a huge meeting with over 9,000 delegates. One of the most important presentations (based on media response) was by Dr. Joseph Ragaz, medical oncologist and clinical professor at the School of Population and Public Health at the University of British Columbia at Vancouver, Canada.
His study stunned many if not most listeners in that it contradicted previous results reported by the Women-s Health Initiative study on estrogen replacement therapy back in 2002. In the Ragaz study, women who received estrogen replacement alone showed a 30-40 percent reduction in breast cancer. These were women who had had previous hysterectomies. His conclusion was that exogenous (administered) estrogen has a protective effect, while endogenous (self produced) estrogen can be carcinogenic.